Delisting risk
Citius Pharmaceuticals (CTXR)
Commercializes LYMPHIR for cutaneous T-cell lymphoma while developing infection, hemorrhoid, and cell-therapy programs.
$0.5731
Pre-market−0.01 (−2.02%)
At close$0.5849(+2.78%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions40 holders · as of Mar 31, 2026 | 3.63% | 996.9K shares | |
| Strategic holders1 holder · as of Feb 17, 2026 | 8.72% | 2.39M shares | |
| Otherremainder | 87.65% | 24.06M shares |
27.45M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (27.45M in the company's Sep 3, 2026 report, 11.17M elsewhere); stakes use the report.
Institutions13F, as of Mar 31, 2026
40 holders · 996.9K shares · 9 new positions · 15 increased · 8 reduced · 10 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Geode Capital Management, LLC | 246.2K | 0.90% | +118.6K | May 15, 2026 |
| Vanguard Capital Management LLC | 167.7K | 0.61% | +167.7Knew | May 15, 2026 |
| Vanguard Fiduciary Trust Co | 77.8K | 0.28% | +77.8Knew | May 8, 2026 |
| BlackRock, Inc. | 69.9K | 0.25% | 0 | May 13, 2026 |
| HRT Financial LP | 60.3K | 0.22% | +60.3Knew | May 14, 2026 |
| Asset Advisory Group, Inc. | 59.0K | 0.21% | 0 | Apr 16, 2026 |
| UBS Group AG | 55.0K | 0.20% | −21.4K | May 5, 2026 |
| Northern Trust Corp | 44.0K | 0.16% | 0 | May 14, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| CVI Investments, Inc. | 9.90% | 2.39M | 13G | Feb 17, 2026 ↗ |
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.